This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Aripiprazole Oral Acceptability Trial

This study has been completed.
Otsuka America Pharmaceutical
Information provided by:
Otsuka Pharmaceutical Development & Commercialization, Inc. Identifier:
First received: January 12, 2005
Last updated: November 7, 2013
Last verified: July 2008
The purpose of this trial is to study liquid aripiprazole in patients with stable schizophrenia.

Condition Intervention Phase
Schizophrenia Drug: Aripiprazole Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Aripiprazole Oral Acceptability Trial

Resource links provided by NLM:

Further study details as provided by Otsuka Pharmaceutical Development & Commercialization, Inc.:

Primary Outcome Measures:
  • acceptability

Estimated Enrollment: 59
Study Start Date: March 2004
Study Completion Date: March 2005
Primary Completion Date: March 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A1 Drug: Aripiprazole
Tablets, Oral, 15 -30 mg, once daily, 2 weeks (days 1 -14).
Other Name: Abilify
Experimental: A2 Drug: Aripiprazole
Oral Solution, Oral, 15-30 ml, once daily, 1 week (days 15 -21).
Other Name: Abilify


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Stable patients currently receiving aripiprazole or other antipsychotic medications.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00101569

United States, California
Local Institution
Anaheim, California, United States
Local Institution
National City, California, United States
United States, Florida
Local Institution
North Miami Beach, Florida, United States
United States, Kansas
Local Institution
Overland Park, Kansas, United States
United States, New York
Local Institution
Staten Island, New York, United States
United States, Oklahoma
Local Institution
Oklahoma City, Oklahoma, United States
United States, Virginia
Local Institution
Falls Church, Virginia, United States
Sponsors and Collaborators
Otsuka Pharmaceutical Development & Commercialization, Inc.
Otsuka America Pharmaceutical
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
  More Information

Additional Information: Identifier: NCT00101569     History of Changes
Other Study ID Numbers: CN138-091
Study First Received: January 12, 2005
Last Updated: November 7, 2013

Additional relevant MeSH terms:
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs processed this record on August 17, 2017